Menu
Targeting
Dysregulated Immune
Cell Signaling
Targeting Dysregulated Immune
Cell Signaling
Kurome® Therapeutics Is Developing Therapies That Target Cancer Cells That Have Co-Opted Immune Signaling Pathways In Order To Avoid Destruction By Traditional Therapeutic Agents And Subvert Adaptive Resistance Mechanisms.
Motivation for Dual IRAK1/4 Inhibition
-
In pre-clinical studies, we have shown that inhibiting IRAK1 and IRAK4 is required to drive maximal efficacy
-
IRAK1 is activated in response to IRAK4 inhibition or degradation
-
Complete inhibition of NF-kB-derived signaling through multiple receptors requires inhibition of both IRAK1 and IRAK4
-
Genetic ablation of both IRAK1 and IRAK4 is more effective in promoting survival in AML xenograft models than is deletion of either kinase alone
Kurome's Approach Differs From Others
-
IRAK1 and IRAK4 utilize distinct and overlapping signaling pathways
-
IRAK1 compensates for IRAK4 inhibition in the setting of leukemia
-
IRAK4 inhibition is insufficient for full efficacy in the setting of leukemia